Rheumatoid Meningitis Occurring during Etanercept Treatment

نویسندگان

  • Koji Tsuzaki
  • Takashi Nakamura
  • Hiroyuki Okumura
  • Naoko Tachibana
  • Toshiaki Hamano
چکیده

We report a 65-year-old man who had repetitive seizures 6 months after receiving etanercept, methotrexate, and prednisolone for rheumatoid arthritis. Mononuclear cells were mildly increased in the cerebrospinal fluid (CSF). Brain magnetic resonance imaging (MRI) showed high intensity along sulci of the frontal and parietal lobes. Brain biopsy revealed lymphocyte and plasma cell infiltration in the meninges, confirming the diagnosis of rheumatoid meningitis. After steroid pulse therapy, seizures resolved and clinical findings improved. When etanercept was replaced by tocilizumab, rheumatoid meningitis did not recur. Although TNF-α inhibitors can control joint symptoms of rheumatoid arthritis, they may induce rheumatoid meningitis.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Aseptic meningitis in a patient taking etanercept for rheumatoid arthritis: a case report

BACKGROUND We report a case of a 53 year old lady recently commenced on etanercept, an anti-TNF (tumour necrosis factor) therapy for rheumatoid arthritis presenting with confusion, pyrexia and an erythematous rash. CASE PRESENTATION A lumbar puncture was highly suggestive of bacterial meningitis, but CSF cultures produced no growth, and polymerase chain reactions (PCR) for all previously repo...

متن کامل

Case Report of Transverse Myelitis in a Patient Receiving Etanercept for Rheumatoid Arthritis

Etanercept is a monoclonal antibody targeted against Tumour Necrosis Factor-alpha (TNF-a) which is an effective treatment for rheumatoid arthritis and is in cases where conventional disease modifying agents such as methotrexate have failed. Neurological complications of treatment have been documented. We describe a case of transverse myelitis occurring in a 48 year-old lady with RA since 1994 w...

متن کامل

Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland.

Etanercept and infliximab are novel biological agents targeted against tumour necrosis factor alpha (TNFalpha), a key cytokine in the pathogenesis of rheumatoid arthritis (RA). We report the results of their use over a two year period in 94 patients with severe inflammatory arthritis. Eighty-eight adults with active inflammatory arthritis (82 with RA), unresponsive to all conventional treatment...

متن کامل

The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis.

OBJECTIVE To evaluate the changes in anti-cyclic citrullinated peptide antibodies (anti-CCP) and rheumatoid factor (RF) following etanercept treatment in patients with rheumatoid arthritis. METHODS The study included 90 patients with rheumatoid arthritis who failed treatment with disease modifying antirheumatic drugs (DMARDs). All patients were allowed to continue treatment with DMARDs; 52 of...

متن کامل

Decreased flares of rheumatoid arthritis during the first year of etanercept treatment: further evidence of clinical effectiveness in the "real world".

OBJECTIVE To determine the incidence of disease flare during the first year of etanercept treatment for 88 patients with rheumatoid arthritis (RA) and compare it with the incidence of flare in those same patients in the year before etanercept use. METHODS The outpatient clinic charts of all patients with RA who were prescribed etanercept in or before September 1999, who also had at least one ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:

دوره 2017  شماره 

صفحات  -

تاریخ انتشار 2017